ConductScience.org, home

Paper42864656PubMed

Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).

Nina W and 17 others. J Clin Apher, 2026.

Cite this record

ConductScience Library. Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE). Papers, record 42864656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42864656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).
Journal
J Clin Apher
Year
2026
Publication types
Journal Article, Randomized Controlled Trial
Revised in PubMed
2026-10-15

Source PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nina WWorelhttps://orcid.org/0000-0002-3599-8099
2Martin SSchrederhttps://orcid.org/0000-0002-1699-9715
3Andreas TTanzmann
4Martin KKurzhttps://orcid.org/0000-0002-2002-8284
5Bianca HKHuber-Kraßnitzer
6Peter NNeumeister
7Konrad RRosskopf
8Nazanin SSareban
9Manuela BBranka
10Vera KKolovratova
11Sophia OOesterreicher
12Beatrix KKoerbler
13Elvira KKitzweger
14Reinhard RRuckser
15Werner RRabitsch
16Hermine AAgishttps://orcid.org/0000-0002-1125-0211
17Maria KKrauth
18T GHGreinix Hildegard

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
CyclamsMajor topic
BenzylaminesMajor topic
Hematopoietic Stem Cell MobilizationMajor topic
Granulocyte Colony-Stimulating FactorMajor topic
Heterocyclic CompoundsMajor topic
Humans
Female
Male
Middle Aged
Double-Blind Method
Aged
Antigens, CD34
Hematopoietic Stem Cell Transplantation
Transplantation, Autologous
Adult
Hematopoietic Stem Cells

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Sanofi GenzymePubMed

Source PubMed

Download CSV of grants

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127042837Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources.Bone Marrow Transplant2016https://conductscience.org/library/papers/27042837PubMed
221658047Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization.Transfusion2012https://conductscience.org/library/papers/21658047PubMed
317994119
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
Bone Marrow Transplant2008https://conductscience.org/library/papers/17994119PubMed
434686447Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience.Clin Lymphoma Myeloma Leuk2022https://conductscience.org/library/papers/34686447PubMed
537655597Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.Leuk Lymphoma2023https://conductscience.org/library/papers/37655597PubMed
638084760Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med2024https://conductscience.org/library/papers/38084760PubMed
741862439
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.
Blood Cancer J2026https://conductscience.org/library/papers/41862439PubMed
824686988Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant2014https://conductscience.org/library/papers/24686988PubMed
921410373Multiple myeloma.N Engl J Med2011https://conductscience.org/library/papers/21410373PubMed
1024141007Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.Biol Blood Marrow Transplant2014https://conductscience.org/library/papers/24141007PubMed
1127578390Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.J Clin Apher2017https://conductscience.org/library/papers/27578390PubMed
1238361116Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.Bone Marrow Transplant2024https://conductscience.org/library/papers/38361116PubMed
1325540889Multiple myeloma.Lancet2015https://conductscience.org/library/papers/25540889PubMed
1439638882Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma.Bone Marrow Transplant2025https://conductscience.org/library/papers/39638882PubMed
1537300386Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.Blood2023https://conductscience.org/library/papers/37300386PubMed
1623179838Colony forming cell assays for human hematopoietic progenitor cells.Methods Mol Biol2013https://conductscience.org/library/papers/23179838PubMed
1722001752Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.Biol Blood Marrow Transplant2012https://conductscience.org/library/papers/22001752PubMed
1828580637Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes.Transfusion2017https://conductscience.org/library/papers/28580637PubMed
1919363221Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood2009https://conductscience.org/library/papers/19363221PubMed
2021625224Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.Bone Marrow Transplant2012https://conductscience.org/library/papers/21625224PubMed

See all 26 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42864656

GET https://conductscience.org/api/papers/v1/42864656/references?page=2